SCHEMBL716341

SCHEMBL716341

O=C(O)NCc1cc2cccc(Cl)c2nc1Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.50
DRD4 P21917 1/20 0.50
DRD3 P35462 1/20 0.50
FAAH O00519 1/20 0.42
PIK3CD O00329 1/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
TERT O14746 2/20 0.39
ADORA2A P29274 1/20 0.39
ADORA1 P30542 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TP53 P04637 1/20 0.39
CNR2 P34972 2/20 0.38
LMNA P02545 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713671 0.87 DRD4 (0.66) L3MBTL1DRD4DRD3FAAHPIK3CD
SCHEMBL8614 0.86 DRD4 (0.45) L3MBTL1DRD4DRD3FAAHPIK3CD
SCHEMBL14047560 0.77 DRD4 (0.44) L3MBTL1DRD4DRD3FAAHPIK3CD
SCHEMBL1886805 0.77 KMT2A (0.46) L3MBTL1DRD4DRD3FAAHPIK3CD
SCHEMBL3711668 0.75 MTNR1A (0.39) L3MBTL1DRD4DRD3PIK3CD
SCHEMBL4437045 0.74 L3MBTL1 (0.40) L3MBTL1DRD4DRD3FAAHPIK3CD
SCHEMBL17530776 0.73 PIK3CD (0.47) PIK3CDKMT2A
SCHEMBL1886928 0.73 DRD4 (0.55) L3MBTL1DRD4DRD3FAAHPIK3CD
SCHEMBL24597723 0.72 MEN1 (0.47) ALDH1A1MEN1KMT2A
SCHEMBL29750489 0.72 MEN1 (0.47) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2403847-B1 TRIAZINE DERIVATIVES AS KINASE INHIBITORS UCB BIOPHARMA SPRL (BE) 2016-03-02 EP disclosed
US-8785628-B2 Triazine derivatives as kinase inhibitors UCB PHARMA, S.A. (BE) 2014-07-22 US disclosed
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors UCB PHARMA, S.A. (BE) 2012-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053167-A1 Triazine Derivatives as Kinase Inhibitors MAP3K15, PI4KA, MAP3K20 L3MBTL1 2277/4885DRD4 4169/4885DRD3 2337/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.